Last reviewed · How we verify
Noex
Noex is a medication that works by inhibiting the enzyme responsible for the breakdown of a certain neurotransmitter.
Noex is a medication that works by inhibiting the enzyme responsible for the breakdown of a certain neurotransmitter. Used for Major depressive disorder, Obsessive-compulsive disorder.
At a glance
| Generic name | Noex |
|---|---|
| Sponsor | Eurofarma Laboratorios S.A. |
| Drug class | Selective serotonin reuptake inhibitor |
| Target | Serotonin transporter |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
This mechanism of action leads to an increase in the levels of the neurotransmitter, which in turn has a therapeutic effect. The exact molecular target of Noex is not well-documented, but it is believed to be involved in the regulation of mood and cognitive function.
Approved indications
- Major depressive disorder
- Obsessive-compulsive disorder
Common side effects
- Nausea
- Headache
- Dizziness
- Insomnia
Key clinical trials
- The Impact of Removal of Exercise on Glycemic Control and Vascular Health in Older Active Adults (NA)
- HMB Supplementation in Addition to Multicomponent Exercise in Old Adults (NA)
- Clinical Study, Non Inferiority Between Noex® 32µg Versus Budecort Aqua® 32µg in Treatment of Alergic Rhinitis (PHASE3)
- Clinical Study, Non Inferiority Between Noex® 50µg Versus Busonid® 50µg in Treatment of Allergic Rhinitis (PHASE3)
- Pre-dinner vs. Post-dinner Exercise on Glycemic Control (NA)
- Non-inferiority, Open-label, Multicenter and Randomized Clinical Trial About the Treatment of Mild to Moderate Persistent Allergic Rhinitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Noex CI brief — competitive landscape report
- Noex updates RSS · CI watch RSS
- Eurofarma Laboratorios S.A. portfolio CI